The resulting cRGD-LHT7 binds to both αvβ3 integrin expressed on the surface of tumor and endothelial cells and to VEGF, resulting in a strong antiangiogenic, anti-tumor activity [321]. The gene discussed is VEGFA; the disease is neoplasm.